Neurology Edition: Top Headlines for Week of October 3, 2022

In this edition, lecanemab study shows reduction in clinical decline for early AD; multimorbidity associated with increased risk for dementia, Crenezumab not effective in treating Alzheimer's disease and more.

Read the full coverage here:

Phase 3 study of lecanemab shows reduction in clinical decline in patients with early AD

Multimorbidity associated with increased risk for dementia

Crenezumab not effective in treating Alzheimer's disease

FDA approves macrocyclic GBCA for contrast-enhanced MRI

Healthy habits in midlife may help delay onset of cognitive decline

References:

Calvin CM, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.32124.

Ostrowitzki S, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2909.

Press Release

Press Release

Small G. What’s preventing us from preventing dementia? Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas.